Cosmo Pharmaceuticals NV represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to innovation and advances in pharmaceutical research and development. With a focus on delivering solutions that address unmet medical needs, Cosmo Pharmaceuticals NV strives to improve the quality of life for patients worldwide. It emphasizes integrity, transparency, and ethical behavior in all aspects of its business. By prioritizing patient well-being and fostering collaboration with healthcare professionals, Cosmo Pharmaceuticals NV aims to create value for its stakeholders while making a positive impact on society.

Cosmo Pharmaceuticals NV is primarily present in various countries and regions across the globe. The company operates in numerous markets, including Europe, where it has a strong presence in countries like Italy, Germany, France, and the United Kingdom. Cosmo Pharmaceuticals NV also has a significant presence in the United States, where it focuses on expanding its market reach. Additionally, the company has established its presence in other regions, such as Asia and Latin America, expanding its business operations and accessing diverse markets. With a global footprint, Cosmo Pharmaceuticals NV continues to leverage its presence in various countries and regions to drive growth and deliver its innovative healthcare solutions.

Cosmo Pharmaceuticals NV has achieved several significant milestones. One notable achievement is the successful development and commercialization of its innovative drug delivery technologies, such as MMX® and Osmotic Controlled Release Oral Delivery System (OROS®). These technologies have transformed the way certain medications are administered, improving patient outcomes and comfort. Additionally, the company has secured numerous partnerships and collaborations with leading pharmaceutical companies, facilitating the global distribution of its products. Furthermore, Cosmo Pharmaceuticals NV has gained regulatory approvals for several products, expanding its portfolio and reinforcing its position as a trusted healthcare provider.

Cosmo Pharmaceuticals NV is a leading pharmaceutical company with a rich history and background. Established in (year), Cosmo Pharmaceuticals NV has emerged as a prominent player in the healthcare industry. The company specializes in developing innovative and advanced pharmaceutical products to improve patient outcomes. With a focus on research and development, Cosmo Pharmaceuticals NV has achieved significant milestones, including (mention key achievements or breakthroughs). Leveraging its expertise and strategic collaborations, the company is driven by a commitment to addressing unmet medical needs and enhancing global healthcare. Cosmo Pharmaceuticals NV continues to pave the way for groundbreaking pharmaceutical solutions, making it a trusted name in the industry.

The main competitors of Cosmo Pharmaceuticals NV in the market include pharmaceutical companies such as AbbVie Inc., Amgen Inc., Novartis AG, Pfizer Inc., and Johnson & Johnson.

Cosmo Pharmaceuticals NV is primarily active in the pharmaceutical industry.

The business model of Cosmo Pharmaceuticals NV focuses on the development and commercialization of innovative therapies in the pharmaceutical industry. Cosmo Pharmaceuticals NV specializes in the research and development of gastrointestinal drugs, utilizing its proprietary drug delivery technologies to enhance the efficacy and safety of treatments. By collaborating with strategic partners, Cosmo Pharmaceuticals NV aims to bring novel treatments to market, improving patient outcomes and addressing unmet medical needs. With its expertise in pharmaceuticals and drug delivery, Cosmo Pharmaceuticals NV strives to create value for patients, healthcare providers, and stakeholders in the healthcare sector.

Cosmo Pharmaceuticals P/E-luku on 10,83.

Cosmo Pharmaceuticals KUV on 4,96.

AlleAktien Laatuscore Cosmo Pharmaceuticals on 5/10.

odotettu Cosmo Pharmaceuticals liikevaihto on 269,85 milj. EUR.

odotettu Cosmo Pharmaceuticals voitto on 123,69 milj. EUR.

Cosmo Pharmaceuticals NV is an international company based in Dublin, Ireland, specializing in the development and marketing of innovative pharmaceutical products and medical devices. The company is divided into three main areas: Pharma, Licensing, and Litigation. In the Pharma division, Cosmo Pharmaceuticals focuses on the development of new drugs, particularly in the fields of gastroenterology, oncology, and respiratory diseases. Some of the company's key products include ELUXADOLINE, a drug for the treatment of irritable bowel syndrome, Methylene Blue MMX, an alternative to Cologuard for colon cancer screening, and Rifamycin SV MMX, an antibiotic for the treatment of diarrhea. Cosmo's products are known for their special formulations and active ingredients, which aim to provide improved efficacy and tolerability. In the Licensing division, Cosmo Pharma also markets its products internationally and has a global presence in over 100 countries. The company has established strategic partnerships with leading pharmaceutical companies such as Warner Chilcott, Sanofi, GSK, and Dr. Falk Pharma to market its products on a global scale. Cosmo leverages its expertise in research, development, and manufacturing of pharmaceutical products to collaborate with other companies through licensing agreements that grant exclusive rights for the distribution of its products in specific countries or regions. Litigation, the company's third main area, involves the enforcement and defense of patents and intellectual property related to Cosmo Pharmaceuticals' products and technologies. The focus also includes the review of applications for market approval by the European Medicines Agency and the US Food and Drug Administration. Cosmo Pharmaceuticals relies on a wide range of products and an efficient business strategy based on the exploration and marketing of innovative solutions for medical inadequacies. The company focuses on differentiating itself in its target markets by putting the needs of patients and doctors at the forefront and offering individualized treatment options. Overall, Cosmo Pharmaceuticals is a strong, expanding company focused on continuous innovation and growing international presence. The company's products and services have the potential to improve healthcare worldwide and enhance the quality of life for millions of people.

Cosmo Pharmaceuticals maksaa osinkoa 0,95 EUR, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Cosmo Pharmaceuticals:lle tai yhtiö ei maksa osinkoa.

Cosmo Pharmaceuticals:n ISIN on NL0011832936.

Cosmo Pharmaceuticals:n WKN on A2AJ68.

Cosmo Pharmaceuticals:n tunnus on COPN.SW.

Viimeisen 12 kuukauden aikana Cosmo Pharmaceuticals maksoi osinkoa 1,05 EUR edestä. Tämä vastaa noin 1,26 % osinkotuottoa. Seuraavan 12 kuukauden aikana Cosmo Pharmaceuticals maksanee ennusteiden mukaan 1,05 EUR osingon.

Cosmo Pharmaceuticals:n tämänhetkinen osinkotuotto on 1,26 %.

Cosmo Pharmaceuticals maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina heinäkuu, kesäkuu, kesäkuu, elokuu.

Cosmo Pharmaceuticals maksoi osinkoa joka vuosi viimeisten 8 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 1,05 EUR suuruisia osinkoja. Tämä vastaa 1,27 % osinkotuottoa.

Cosmo Pharmaceuticals kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Cosmo Pharmaceuticals osingon 12.7.2024, jonka suuruus on 2 EUR, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 10.7.2024.

Viimeisin osinko maksettiin 12.7.2024.

Vuonna 2023 Cosmo Pharmaceuticals maksoi 0,95 EUR osinkoina.

Cosmo Pharmaceuticals:n osingot maksetaan EURssa.